
Ask a doctor about a prescription for BLIZOMIT 10 mg/mL + 5 mg/mL EYE DROPS, SUSPENSION
Package Leaflet: Information for the User
Blizomit 10mg/ml + 5mg/ml eye drops, suspension
brinzolamida/timolol
Read the package leaflet carefully before you start using this medicine because it contains important information for you.
Contents of the package leaflet
Blizomit contains two active substances, brinzolamida and timolol, which work together to reduce the pressure inside the eye.
This medicine is used to treat high pressure in the eyes, also called glaucoma or ocular hypertension, in adult patients over 18 years of age and in those who cannot be effectively controlled with a single medication.
Do not use Blizomit
Warnings and precautions
Use this medicine only in your eye(s).
If you have signs of hypersensitivity or severe reactions, stop using this medicine and consult your doctor.
Consult your doctor or pharmacist before starting to use this medicine if you have or have had in the past:
Be careful with this medicine:
Severe skin reactions, including Stevens-Johnson syndrome and toxic epidermal necrolysis, have been reported in association with brinzolamida treatment. Stop using this medicine and seek medical attention immediately if you notice any of the symptoms related to these severe skin reactions described in section 4.
Children and adolescents
This medicine is not recommended for children and adolescents under 18 years of age.
Other medicines and Blizomit
Tell your doctor or pharmacist if you are using, have recently used, or might use any other medicines.
This medicine may affect, or be affected by, other medicines you are using, including other eye drops for the treatment of glaucoma. Consult your doctor if you are using or think you might use medicines to lower blood pressure, such as parasimpaticomimetics and guanethidine, or other heart medicines, including quinidine (used to treat heart conditions and some types of malaria), amiodarone, or other medicines to treat heart rhythm disorders, and glycosides to treat heart failure. Also, consult your doctor if you are using or think you might use medicines to treat diabetes or to treat stomach ulcers, antifungal, antiviral, or antibiotic medicines, or antidepressants such as fluoxetine and paroxetine.
Consult your doctor if you are using another carbonic anhydrase inhibitor (acetazolamide or dorzolamide).
It has been occasionally reported an increase in pupil size when using this medicine with adrenaline (epinephrine).
Pregnancy and breastfeeding
If you are pregnant, think you may be pregnant, or plan to become pregnant, do not use this medicine unless your doctor considers it necessary. Consult your doctor before using this medicine.
Do not use this medicine during breastfeeding, as timolol may pass into breast milk. Consult your doctor before using any medicine during breastfeeding.
Driving and using machines
Do not drive or use machines until your vision is clear. Immediately after applying this medicine, you may notice that your vision becomes blurry for a while.
One of the active ingredients may worsen the ability to perform tasks that require mental alertness and/or physical coordination. If you notice these effects, be careful when driving or using machines.
Blizomit contains benzalkonium chloride
This medicine contains 1.7 µg of benzalkonium chloride per drop (= 1 dose), equivalent to 0.1 mg/ml.
Benzalkonium chloride can be absorbed by soft contact lenses and may alter the color of the contact lenses. Remove contact lensesbefore using this medicine and wait 15 minutes before putting them back. Benzalkonium chloride may cause eye irritation, especially if you have dry eyes or other corneal diseases (the transparent layer of the front of the eye). Consult your doctor if you feel any unusual sensation, itching, or pain in the eye after using this medicine.
Follow exactly the administration instructions of this medicine indicated by your doctor or pharmacist. In case of doubt, consult your doctor or pharmacist again.
In the event that this medicine replaces a previous eye drop used for the treatment of glaucoma, discontinue the use of the previous medicine and start using this medicine the next day. In case of doubt, consult your doctor or pharmacist.
To avoid possible contamination of the dropper tip and the suspension, you should be careful not to touch the eyelids, the area around them, or other surfaces with the dropper. You should keep the bottle well closed when not in use.
The following instruction is useful to reduce the amount of medicine that passes into the bloodstream after applying the eye drops:
The recommended dose is
One drop in the affected eye(s), twice a day.
This medicine should only be applied to both eyes if your doctor has recommended it. Follow the treatment for the entire period of time indicated by your doctor.
How to use



1 2 3
If a drop falls outside the eye, try again.
If you are using another eye drop or ointment, wait at least 5 minutes between applying each medicine. Eye ointments should be administered last.
If you use more Blizomit than you should, you can rinse your eyes with warm water. Do not apply more drops until it is time for the next dose.
You may experience a decrease in heart rate, decrease in blood pressure, heart failure, difficulty breathing, and effects on the nervous system.
In case of overdose or accidental ingestion, consult your doctor or pharmacist immediately or call the Toxicology Information Service, phone 91 562 04 20, indicating the medicine and the amount used.
If you forget to use Blizomit, continue with the next dose that was scheduled. Do not apply a double dose to make up for the forgotten doses. Do not apply more than one drop twice a day in the affected eye(s).
If you stop using Blizomitwithout consulting your doctor, the pressure in your eye will not be controlled, which could lead to loss of vision.
If you have any other questions about the use of this medicine, ask your doctor or pharmacist.
Like all medicines, this medicine can cause adverse effects, although not all people suffer from them.
Stop using Blizomit and seek immediate medical attentionif you notice any of the following symptoms:
Unless the effects are severe, continue with the treatment as usual. If these effects concern you, consult your doctor or pharmacist. Do not stop using this medicine without consulting your doctor first.
Frequent adverse effects (may affect up to 1 in 10 people)
Infrequent adverse effects (may affect up to 1 in 100 people)
Rare adverse effects (may affect up to 1 in 1,000 people)
Frequency not known (cannot be estimated from available data)
Reporting of Adverse Effects
If you experience any type of adverse effect, consult your doctor or pharmacist, even if it is a possible adverse effect not listed in this leaflet. You can also report them directly through the Spanish Pharmacovigilance System for Human Use Medicines: https://www.notificaram.es. By reporting adverse effects, you can contribute to providing more information on the safety of this medicine.
Keep this medicine out of the sight and reach of children.
Do not use this medicine after the expiration date stated on the bottle and carton after "EXP". The expiration date is the last day of the month indicated.
This medicine does not require special storage conditions.
To avoid infections, discard the bottle 4 weeks after the first opening. Write the opening date on the space provided on the bottle label and carton.
Medicines should not be disposed of via wastewater or household waste. Deposit the packaging and medicines you no longer need at the pharmacy's SIGRE point. In case of doubt, ask your pharmacist how to dispose of the packaging and medicines you no longer need. This way, you will help protect the environment.
Composition of Blizomit
Very small amounts of hydrochloric acid and/or sodium hydroxide are added to maintain normal acidity levels (pH levels).
Appearance of the Product and Package Contents
10 ml plastic bottle with a sealed LDPE white dropper tip and an HDPE/LDPE white cap with a tamper-evident seal, containing 5 ml of homogeneous white suspension.
The following package sizes are available: cartons containing 1 x 5 ml, 3 x 5 ml.
Not all package sizes may be marketed.
Marketing Authorization Holder and Manufacturer
Marketing Authorization Holder
Pharmathen S.A.
Dervenakion 6
15351 Pallini, Attiki
Greece
Manufacturer
Pharmathen S.A.
Dervenakion 6
15351 Pallini, Attiki
Greece
Or
Balkanpharma-Razgrad AD
68 Aprilsko vastanie Blvd.,
Razgrad, 7200,
Bulgaria
This medicine is authorized in the Member States of the European Economic Area under the following names:
Germany | Blizomit 10 mg/ml + 5 mg/ml eye drop suspension |
France | BLIZOMIT 10 mg/5 mg per mL, eye drops in suspension |
Spain | Blizomit 10 mg/ml + 5 mg/ml eye drops in suspension |
Greece | BLIZOMIT |
Netherlands | BLIZOMIT |
Portugal | BLIZOMIT |
Italy | BLIZOMIT |
Date of the last revision of this leaflet:September 2023
Detailed information on this medicine is available on the website of the Spanish Agency for Medicines and Health Products (AEMPS) http://www.aemps.gob.es.
The best alternatives with the same active ingredient and therapeutic effect.
Discuss dosage, side effects, interactions, contraindications, and prescription renewal for BLIZOMIT 10 mg/mL + 5 mg/mL EYE DROPS, SUSPENSION – subject to medical assessment and local rules.